ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1420

The Ability of Patients with Early Rheumatoid Arthritis to Taper Low-Dose Glucocorticoids on Methotrexate Monotherapy and in Combination with Adalimumab

Josef S. Smolen1, Prashanth Sunkureddi2, Jaclyn K. Anderson3, Jenny Griffith3, Dingfeng Jiang3, Kun Chen3, Jessica L. Suboticki4 and Arthur Kavanaugh5, 1Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Clear Lake Rheumatology, Nassau Bay, TX, 3AbbVie Inc., North Chicago, IL, 4AbbVie Inc., Mettawa, IL, 5Medicine, University of California, San Diego, La Jolla, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Adalimumab, glucocorticoids and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Low dose glucocorticoids (GCs) are recommended in combination with ≥1 synthetic DMARDs as part of the initial treatment strategy in rheumatoid arthritis (RA), with taper recommended as quickly as is clinically feasible1. The purpose of this analysis was to evaluate the ability of patients (pts) with early RA receiving MTX monotherapy or adalimumab (ADA)+MTX to taper and discontinue low-dose GCs and associated impact on outcomes. 

Methods: This post hoc analysis included MTX naïve pts receiving PBO+MTX or ADA+MTX in the double-period OPTIMA trial. Pts achieving stable low disease activity (sLDA; DAS28 <3.2 at wks 22 and 26) during the first 26 wks (P1) continued blinded therapy (MTX, ADA continuation) for an additional 52 wks (P2). PBO+MTX pts not achieving sLDA were offered open-label (OL) ADA+MTX in P2 (OL ADA rescue). Pts receiving GCs (≤10 mg/d) at baseline (BL) continued a stable dose through P1; tapering ≤1mg/EOW was permitted in P2. Pts were categorized by GC use in each treatment group. The proportions of pts discontinuing GC were summarized. Outcomes were assessed as change from wk 26 to wk 78. Adverse events (AEs) were summarized.         

Results: Of the 926 pts who entered P2 (RA disease duration ~4 months), 207/460 (45%) and 188/466 (40%) in the initial PBO+MTX and ADA+MTX groups, respectively, had GC treatment at BL. BL characteristics appeared similar between pts receiving and not receiving GCs. In P1, the proportions of pts achieving sLDA between those receiving and not receiving GCs in the PBO+MTX group were similar (51% without and 49% with GCs), while in the ADA+MTX group a higher proportion of pts achieved sLDA without GCs (58% without vs 42% with GCs). At the beginning of P2, 54/112 (48%) and 45/105 (43%) pts in the MTX and ADA continuation groups, respectively, were on GCs; 145/348 (42%) pts in the OL ADA rescue group received GCs. Of these pts, equal proportions [57% (n=31), 56% (n=25), and 57% (n=83) from the MTX continuation, ADA continuation, and OL ADA rescue groups, respectively] discontinued GCs during P2. Although slight increases in disease activity were observed, GC discontinuation across the different groups did not result in clinically meaningful changes through wk 78 (Table). Within the 3 P2 treatment groups, the AE profile appeared similar between those receiving and not receiving GCs. 

Conclusion: Approximately 60% of early RA pts receiving PBO+MTX or ADA+MTX along with GCs whose treatment was modified based on attainment of sLDA were able to discontinue their GC use without clinically meaningful worsening in disease activity, structural damage or decreases in function. As the current analysis is limited by its retrospective, uncontrolled nature, further studies are needed to prospectively evaluate the ability of pts with early RA to taper or discontinue GCs.  

Reference:

1.    Smolen JS, et al. Ann Rheum Dis 2017;76(6):960-977.


Disclosure: J. S. Smolen, AbbVie, Inc., Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, and UCB, 5,AbbVie, Inc., Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, and UCB, 2; P. Sunkureddi, Novartis, BMS, UCB, Pfizer, AbbVie Inc., and Takeda, 5,Novartis, BMS, UCB, Pfizer, AbbVie Inc., and Takeda, 8; J. K. Anderson, Abbvie Inc, 3,AbbVie Inc, 3; J. Griffith, AbbVie, 1,AbbVie, 3; D. Jiang, AbbVie Inc, 1,AbbVie Inc, 3; K. Chen, AbbVie Inc, 1,AbbVie Inc, 3; J. L. Suboticki, AbbVie Inc, 1,AbbVie Inc, 3; A. Kavanaugh, AbbVie, Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB., 2.

To cite this abstract in AMA style:

Smolen JS, Sunkureddi P, Anderson JK, Griffith J, Jiang D, Chen K, Suboticki JL, Kavanaugh A. The Ability of Patients with Early Rheumatoid Arthritis to Taper Low-Dose Glucocorticoids on Methotrexate Monotherapy and in Combination with Adalimumab [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-ability-of-patients-with-early-rheumatoid-arthritis-to-taper-low-dose-glucocorticoids-on-methotrexate-monotherapy-and-in-combination-with-adalimumab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-ability-of-patients-with-early-rheumatoid-arthritis-to-taper-low-dose-glucocorticoids-on-methotrexate-monotherapy-and-in-combination-with-adalimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology